Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20040647 | 0.88 | TP53 (0.45) | MTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL16295456 | 0.85 | MTNR1A (0.57) | MTNR1AMTNR1BHRH1CCR3TAAR1 | |
| SCHEMBL31181340 | 0.85 | MTNR1A (0.57) | MTNR1AMTNR1BHRH1CCR3TAAR1 | |
| SCHEMBL20981738 | 0.82 | MTNR1A (0.40) | MTNR1AMTNR1BTAAR1 | |
| SCHEMBL3812917 | 0.81 | MAOA (0.38) | MTNR1AMTNR1BACHEMAOAMAOB | |
| SCHEMBL17400964 | 0.80 | APP (0.44) | MTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL6605400 | 0.79 | MAOA (0.37) | MTNR1AMTNR1BACHEMAOAMAOB | |
| SCHEMBL22468935 | 0.79 | BACE1 (0.44) | MTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL7867405 | 0.79 | EPHX1 (0.40) | MAOAMAOB | |
| SCHEMBL5313175 | 0.79 | MTNR1A (0.58) | MTNR1AMTNR1BHRH1CCR3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497386-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2024-09-19 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11384068-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11384068-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-109328187-B | Novel compound with FGFR (FGFR) inhibitory activity as well as preparation and application thereof | 中国科学院上海药物研究所 | 2022-04-26 | — | — | CN | disclosed |
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS HEALTH, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2019144132-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| US-6756388-B1 | HAVING PIPERIDINYL AND PHENOLIC FUNCTIONALITY; BONE LOSS; BREAST OR PROSTATE CANCER | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003106462-A1 | BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-0723537-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010513-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0129478-B1 | 2-SULFAMOYLBENZO (B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4788192-A | TOPICALLY APPLYING; FOR GLAUCOMA | MERCK & CO., INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4668697-A | Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0129478-A2 | 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347032-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | MTNR1A 46/4885MTNR1B 51/4885HRH1 1349/4885 |
| US-20240308986-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | MTNR1A 46/4885MTNR1B 51/4885HRH1 1349/4885 |
| US-20220332704-A1 | ESTROGEN RECEPTOR-MODULATING COMPOUNDS | ESR2, GPER1, ESR1 | MTNR1A 46/4885MTNR1B 51/4885HRH1 1349/4885 |
| US-11384068-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | MTNR1A 46/4885MTNR1B 51/4885HRH1 1349/4885 |
| US-12018019-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | MTNR1A 46/4885MTNR1B 51/4885HRH1 1349/4885 |
| US-20040186126-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | MTNR1A 2925/4885MTNR1B 2598/4885HRH1 177/4885 |
| US-12497386-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | MTNR1A 46/4885MTNR1B 51/4885HRH1 1349/4885 |
| US-20040009965-A1 | Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | DPYD, DHFR, TYMP | MTNR1A 2925/4885MTNR1B 2598/4885HRH1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.